3 growth greats for your shares portfolio! AstraZeneca plc, Diageo plc and Wizz Air Holdings plc

Royston Wild explains why profits should pump higher at AstraZeneca plc (LON: AZN), Diageo plc (LON: DGE) and Wizz Air Holdings plc (LON: WIZZ).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today I am looking at three Footsie stars set to deliver stunning returns.

Beverages beauty

I have long argued that spirits manufacturer Diageo (LSE: DGE) is a terrific growth option thanks to its robust position in established and emerging regions alike.

And although adverse currency movements — not to mention wider economic turbulence — from its ‘new’ territories look set to persist in the immediate future, I reckon the strength of Diageo’s labels should deliver solid long-term revenues growth.

Brands like Captain Morgan rum, Johnnie Walker whisky and Guinness stout carry customer loyalty like no others, allowing Diageo to raise prices to counter other pressures affecting the top line. And a steady string of innovations across these top-level labels promises to keep drinkers thirsting for more.

City brokers also share my bullish take, and Diageo is expected to bounce from a 1% earnings decline for the period to June 2016 with a 9% advance in fiscal 2017.

Although ‘toppy’ on paper, I reckon subsequent P/E ratios of 20.8 times and 19.1 times respectively represent decent value given Diageo’s hot growth profile.

Flying high

I believe cheap flyer Wizz Air (LSE: WIZZ) is also a terrific selection for those seeking electric earnings growth in the years ahead.

Stable economic conditions in Europe continue to propel holidays demand, and consequently sales of Wizz Air’s budget seats. But even if near-term turbulence hits travellers’ wallets, the budget airline should continue to enjoy solid revenues growth as flyers switch down from more expensive operators.

On top of this, Wizz Air is also expanding the number of routes it operates, a factor that helped drive passenger numbers 21% higher in the year to March 2016, to 20m.

The City expects earnings to jump 26% and 16% in 2017 and 2018 respectively. I reckon subsequent P/E ratings of 12.8 times and 11.2 times for these years are too good to pass up.

Pharma fizzer

While colossal patent losses are expected to keep AstraZeneca’s (LSE: AZN) bottom line under pressure for some time yet, I believe the splendid progress of its product pipeline return should deliver handsome returns for patient investors.

Just this month AstraZeneca announced that it expects to submit its Benralizumab asthma drug for regulatory approval in the US and Europe later this year following encouraging Phase III testing data.

The firm was also left to cheer news that the US Food and Drug Administration had given its Selumetinib thyroid cancer treatment orphan drug designation — the product has also been touted as a future sales star. And I expect the good news to keep on coming as AstraZeneca throws huge sums into organic R&D investment and additional bolt-on acquisitions in fast-growing therapy segments.

So although the pharma play is expected to endure earnings slips of 7% and 2% in 2015 and 2016 correspondingly, I reckon a consequent earnings multiple of 14.1 times for the current period marks a decent time to latch onto AstraZeneca’s exciting growth prospects.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca and Diageo. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young Woman Drives Car With Dog in Back Seat
Investing Articles

Can the Tesla share price beat September’s 22% climb in October?

All the techie attention seems to have drifted away from the Tesla share price at the moment. But October could…

Read more »

Investing Articles

Up 27% yesterday, but I think my favourite growth stock under $10 still has room to run

Our writer looks at why up-and-coming growth stock Joby Aviation (NYSE:JOBY) just exploded 27% higher on the New York Stock…

Read more »

Investing Articles

1 stock I’d love to buy from the FTSE 100 in October

I think this FTSE 100 business has great potential to perform well long term and the valuation looks attractive to…

Read more »

Investing Articles

If I’d put £1,000 in Lloyds shares 5 years ago, here’s what I’d have now

Lloyds shares are among the most closely watched on the FTSE 100. The stock might not have delivered for investors…

Read more »

Investing Articles

Top UK shares I’d consider buying for growing dividends

Some UK shares have been super-reliable when it comes to throwing cash back at investors. Paul Summers picks out some…

Read more »

Investing Articles

After a bumper first half gives the Tesco share price a boost, should I buy?

The Tesco share price is having a great year, and these first-half figures show us why. Here's how the stock…

Read more »

One English pound placed on a graph to represent an economic down turn
Investing Articles

Fear sends FTSE 100 stocks flashing red. But why are these two stocks winning?

The FTSE 100 continues to deliver a strong performance despite several stocks dipping earlier this week. Our writer looks at…

Read more »

Investing Articles

1 stock I’d love to buy for growth, dividends, and share buybacks

Stephen Wright thinks resilient share buybacks and a strong competitive position make a stock with a 2% dividend yield a…

Read more »